In vitro (human MSC) · PMID 37782636
KE peptide regulates SIRT1, PARP1 and PARP2 gene expression and protein synthesis in human mesenchymal stem cells — VialBase Research
Most directly Vilon-specific molecular study; underpins the SIRT1/PARP mechanism described on the compound page.
Last updated · 2023 · Khavinson VK et al. · Adv Gerontol
Key findings
- The KE dipeptide (Vilon) modulated expression of SIRT1, PARP1 and PARP2 — genes central to sirtuin signalling and DNA repair
- Supports an epigenetic, gene-regulatory mechanism for the dipeptide rather than receptor binding
- Conducted in human mesenchymal stem cells, an ageing-relevant model
KE (Vilon) regulation of SIRT1/PARP gene expression (PMID: 37782636)
Summary
In human mesenchymal stem cells, the KE dipeptide (Vilon) altered expression of SIRT1, PARP1 and PARP2 and associated protein synthesis — genes tied to DNA repair, sirtuin signalling and cellular ageing.
Relevance
This is the clearest compound-specific evidence for Vilon‘s proposed epigenetic, gene-regulatory mechanism. It is in vitro, not a clinical outcome study.
See Also
- Parent compound: Vilon
Where to buy Vilon
Vilon5 vetted vendors
BioLongevity LabsVisit BioLongevity Labs →
Save 15% with code VIALBASE
VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.